Check Out What Whales Are Doing With AMGN
Check Out What Whales Are Doing With AMGN
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen.
擁有大量資金的鯨魚對安進採取了明顯的看淡立場。
Looking at options history for Amgen (NASDAQ:AMGN) we detected 67 trades.
查看納斯達克股票代碼爲AMGN的期權歷史，我們檢測到67項交易。
If we consider the specifics of each trade, it is accurate to state that 31% of the investors opened trades with bullish expectations and 49% with bearish.
如果我們考慮每筆交易的具體情況，可以準確地說，31%的投資者以看漲的預期開倉，49%以看跌開倉。
From the overall spotted trades, 19 are puts, for a total amount of $647,913 and 48, calls, for a total amount of $1,489,311.
從整個被發現的交易中，有19個看跌期權交易，交易總金額爲$647,913，48個看漲期權交易，交易總金額爲$1,489,311。
Predicted Price Range
預測價格區間
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $250.0 to $330.0 for Amgen over the last 3 months.
考慮這些合同的成交量和未平倉量，似乎鯨魚過去三個月一直將安進的價格範圍定在$250.0到$330.0之間。
Analyzing Volume & Open Interest
分析成交量和未平倉合約
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 826.38 with a total volume of 28,191.00.
就流動性和利率而言，安進期權交易的平均未平倉量今天爲826.38，總成交量爲28,191.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $250.0 to $330.0 over the last 30 days.
在下圖中，我們可以跟蹤過去30天內安進大手筆期權交易的看漲和看跌期權的成交量和未平倉量的發展情況，它們的執行價格範圍爲$250.0到$330.0。
Amgen Option Volume And Open Interest Over Last 30 Days
安進期權成交量和未平倉量在過去30天內的情況
Largest Options Trades Observed:
觀察到的最大期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | BEARISH | 01/17/25 | $28.55 | $27.85 | $28.55 | $315.00 | $97.0K | 1073 | |
| AMGN | CALL | SWEEP | BEARISH | 01/17/25 | $16.9 | $16.7 | $16.7 | $330.00 | $66.5K | 835183 | |
| AMGN | CALL | SWEEP | BULLISH | 01/17/25 | $16.75 | $16.3 | $16.65 | $330.00 | $66.4K | 8350 | |
| AMGN | CALL | SWEEP | BULLISH | 01/17/25 | $17.2 | $16.4 | $16.5 | $330.00 | $59.4K | 8351.3K | |
| AMGN | CALL | SWEEP | BULLISH | 01/17/25 | $16.45 | $16.35 | $16.45 | $330.00 | $49.1K | 8351.5K |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看跌 | SWEEP | 看淡 | 01/17/25 | $28.55 | $27.85 | $28.55 | $315.00 | $97.0K | 1073 | |
| AMGN | 看漲 | SWEEP | 看淡 | 01/17/25 | 16.9美元 | $16.7 | $16.7 | $330.00 | $66.5K | 835183 | |
| AMGN | 看漲 | SWEEP | 看好 | 01/17/25 | $16.75 | 16.3美元 | $16.65 | $330.00 | $66.4K | 8350 | |
| AMGN | 看漲 | SWEEP | 看好 | 01/17/25 | $17.2 | $16.4 | $16.5 | $330.00 | $59.4K | 8351.3K | |
| AMGN | 看漲 | SWEEP | 看好 | 01/17/25 | $16.45 | $16.35 | $16.45 | $330.00 | $49.1K | 8351.5K |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是生物技術製藥領域的領導者。旗艦藥物包括增加紅細胞計數的艾普畢與阿拉尼許、增強免疫系統的奈帕姆和奈烏細胞移植因子、以及針對炎症性疾病的恩布瑞爾和歐特茲拉。安進在2006年推出了首個癌症治療藥物Vectibix，並推出了增強骨密度的藥物Prolia/Xgeva（於2010年獲批）和Evenity（於2019年獲批）。對Onyx的收購增強了該公司在治療腫瘤領域的藥物組合，其中包括Kyprolis。最近推出的藥物包括Repatha（降低膽固醇）、Aimovig（緩解偏頭痛）、Lumakras（治療肺癌）以及Tezspire（治療哮喘）。2023年Horizon收購帶來了幾種罕見疾病藥物，其中包括治療甲狀腺眼病的Tepezza。安進還擁有不斷增長的生物類似物組合。
Following our analysis of the options activities associated with Amgen, we pivot to a closer look at the company's own performance.
在我們分析與安進相關的期權活動之後，我們將轉向更仔細地研究公司自身的表現。
Present Market Standing of Amgen
安進的現場市場地位
- Currently trading with a volume of 1,071,864, the AMGN's price is down by 0.0%, now at $303.28.
- RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
- Anticipated earnings release is in 44 days.
- 安進的成交量爲1,071,864，價格下跌了0.0%，現價爲$303.28。
- RSI讀數表明該股票目前處於中立狀態，處於超買和超賣之間。
- 預期四十四天後公佈收益。
Expert Opinions on Amgen
安進的專家意見
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $332.0.
過去30天中，共有1位專業分析師對此股票發表了評論，設定平均價格目標爲$332.0。
- Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Amgen, targeting a price of $332.
- RBC Capital的一位分析師維持了對安進的推薦評級，並以$332.0的價格爲目標。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期權與僅交易股票相比是一種更具風險的資產，但它們具有更高的利潤潛力。認真的期權交易者通過每日學習，進出交易，跟隨多個指標並密切關注市場來管理這種風險。
譯文內容由第三人軟體翻譯。